basing pattern over and welcome to nine dollar

The long basing pattern means that the move up should be long and sustained with the backdrop of a $2-4 billion market to be served and with a tiny market cap of 90 million with potential $50 million in cash. This will be the only FDA approved treatment for DME. It lasts 24-36 months and is inserted in a painless method in the office of a retinologist. Pfizer owes $153 million in royalties for milestones or $9 a share. So that is $11.40 a share for a sp of $5.25. However the major play is the very big royalty stream from Alimera Sciences for Iluvien approval with expanding indications in addition to the DME approval. AT P.E of 25 x 2011 est eps of 60 cents you get $15 sp. This could be conservative considering projected 50-75 % + growth for a PEG ratio of 8/50= .16.I believe that Pfizer as a 10% shareholder and oweing $153 in milestone royalties would be wise to buy company. The premium would have to be large considering the terrific growth . Takeout would be $11-13. If get organic growth in any event chart is showing $9-10. I added some shares here.